ReShape Lifesciences to Highlight LAP-Band Weight Loss Technology at ASMBS Spring Meeting
Back to Newsroom
Mentioned in this Article

ReShape Lifesciences to Highlight LAP-Band Weight Loss Technology at ASMBS Spring Meeting

Tuesday, June 18, 2019 8:00 AM
Share this article now
Company Update

SAN CLEMENTE, CA / ACCESSWIRE / June 18, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be exhibiting its products and will have two presentations featuring the Company's proprietary LAP-BAND® technology at the American Society for Metabolic and Bariatric Surgery (ASMBS) Weekend 2019, taking place at the downtown Chicago Marriott from June 20-22, 2019.

In addition to the ReShape Lifesciences exhibit, which will feature the Company's products in the Exhibit Hall, ReShape Lifesciences will be holding two educational presentations.

Details of the presentations:

Thursday, June 20: 5:00PM - 6:00PM

Presentation I: "Dispelling LAP-BAND® Myths"
Presenter: Dr. Fred Tiesenga, MD, Bariatric Surgeon at Westlake Bariatrics in Elmwood Park, IL.

Presentation 2: "Building your LAP-BAND® Practice through Marketing"
Presenters: Dr. Vafa Shayani, MD, General Surgeon at Bariatric Institute of Greater Chicago and Rich Rosenzweig, Founder and CEO Sequence Health

Dr. Tiesenga has implanted over 2,000 LAP-BANDs since 2002. Dr. Tiesenga is the Director of Minimally Invasive and Bariatric Surgery at Westlake Hospital and Vice Chairman of Surgery at West Suburban Hospital. He is also the President of Illinois Association of Bariatric Surgeons.

Dr. Shayani has implanted the LAP-BAND in 3,000 patients since 2001. In his presentation, Dr. Shayani will address how to drive qualified leads through local marketing. He is past President of the Illinois ASMBS Chapter and the current Co-Chair of the Membership Committee. Rich Rosenzweig is the Founder and CEO of Sequence Health, one of the premier lead management and patient engagement programs in the country, and his presentation will discuss how to best manage leads to improve conversion to LAP-BAND procedures.

About ASMBS Weekend 2019

ASMBS Weekend, June 20-22, 2019, is comprised of three full days of specialized surgical and integrated health courses in an intimate setting.

This clinical symposium, hosted at the Chicago Marriott Downtown Magnificent Mile Hotel, is designed for all professions involved in obesity prevention, treatment, and research. This year's comprehensive schedule features a special focus in robotics in bariatrics as well as courses addressing weight regain, revisions and practice optimization.

For more details on ASMBS Weekend, please visit

About ReShape Lifesciences Inc.

ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved Lap-Band® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of the Lap-Band system, including the risk of default under our security agreement with Apollo Endosurgery entered into in connection with the transaction; the risk of default under our secured subordinated convertible debentures due June 28, 2019 that we issued in March 2019; our ability to continue as a going concern if we are unable to improve our operating results or obtain additional financing; risks related to ownership of our securities as a result of our delisting from the Nasdaq Capital Market; our proposed ReShape Vest product may not be successfully developed and commercialized; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system and Lap-Band system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed May 16, 2019 and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.


Investor Contact:

Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
949-429-6680 x106
[email protected]
Debbie Kaster
Investor Relations
Gilmartin Group
[email protected]

SOURCE: ReShape Lifesciences

ReShape Lifesciences Inc.
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: